Pharmaceutical

Novo to buy Catalent: the backlash begins

Novo Nordisk’s plans to buy Catalent has raised objections related to the risk of drug shortages, manufacturing standards, and antitrust violations.

Feb 10, 2024 - 18:00
Novo to buy Catalent: the backlash begins
Novo Nordisk’s plans to buy Catalent has raised objections related to the risk of drug shortages, manufacturing standards, and antitrust violations.
Read the original article

Tags:

Previous Article

Another recall: does Philips have a quality control problem?

Next Article

Pharma and biotech concerned about the stability of large CROs, survey finds

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: We’re reading about Lilly plant problems, FDA reorganization plans, and more

STAT+: Pharmalittle: We’re reading about Lilly plant pr...

Jan 22, 2024

Bavarian Nordic completes travel vaccine deal with Emergent

Bavarian Nordic completes travel vaccine deal with Emer...

May 16, 2023

Opinion: Can Arena Bioworks upend the traditional scientific research model in the U.S.?

Opinion: Can Arena Bioworks upend the traditional scien...

Feb 3, 2024